Currently, there are 160.09M common shares owned by the public and among those 153.03M shares have been available to trade.
The company’s stock has a 5-day price change of -0.49% and -21.39% over the past three months. NVAX shares are trading 109.79% year to date (YTD), with the 12-month market performance up to 58.58% higher. It has a 12-month low price of $3.53 and touched a high of $23.86 over the same period. NVAX has an average intraday trading volume of 6.55 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -13.57%, -16.72%, and 3.58% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Novavax, Inc. (NASDAQ: NVAX) shares accounts for 53.31% of the company’s 160.09M shares outstanding.
It has a market capitalization of $1.61B and a beta (3y monthly) value of 2.05. The earnings-per-share (ttm) stands at -$2.77. Price movements for the stock have been influenced by the stock’s volatility, which stands at 5.18% over the week and 7.20% over the month.
Earnings per share for the fiscal year are expected to increase by 81.38%, and 103.53% over the next financial year. EPS should grow at an annualized rate of 37.90% over the next five years, compared to 11.55% over the past 5-year period.
Looking at the support for the NVAX, a number of firms have released research notes about the stock. JP Morgan stated their Underweight rating for the stock in a research note on July 30, 2024, with the firm’s price target at $8. BofA Securities was of a view on May 10, 2024 that the stock is Neutral, while B. Riley Securities gave the stock Buy rating on August 09, 2023, issuing a price target of $15. TD Cowen on their part issued Market Perform rating on April 20, 2023.
